958 related articles for article (PubMed ID: 19149848)
1. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
[TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
Klukowska A; Windyga J; Batorova A
Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
Windyga J; von Depka-Prondzinski M;
Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience.
Batty P; Chen YH; Bowles L; Hart DP; Platton S; Pasi KJ
Haemophilia; 2014 Nov; 20(6):846-53. PubMed ID: 25102895
[TBL] [Abstract][Full Text] [Related]
9. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
10. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.
Howman R; Barnes C; Curtin J; Price J; Robertson J; Russell S; Seldon M; Suppiah R; Teague L; Barrese G
Haemophilia; 2011 May; 17(3):463-9. PubMed ID: 21118340
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of Wilate in paediatric VWD patients under 6 years of age - results of a prospective multicentre clinical study including recovery information.
Nowak-Göttl U; Krümpel A; Russo A; Jansen M
Haemophilia; 2013 Nov; 19(6):887-92. PubMed ID: 23919249
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
13. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
Auerswald G; Kreuz W
Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
Shortt J; Dunkley S; Rickard K; Baker R; Street A
Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
[TBL] [Abstract][Full Text] [Related]
15. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.
Foster PA
Thromb Haemost; 1995 Nov; 74(5):1370-8. PubMed ID: 8607125
[TBL] [Abstract][Full Text] [Related]
16. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.
Federici AB; Barillari G; Zanon E; Mazzucconi MG; Musso R; Targhetta R; Mannucci PM
Haemophilia; 2010 Jan; 16(1):101-10. PubMed ID: 19811543
[TBL] [Abstract][Full Text] [Related]
18. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
[TBL] [Abstract][Full Text] [Related]
20. Wilate use in 47 children with von Willebrand disease: the North London paediatric haemophilia network experience.
Khair K; Batty P; Riat R; Bowles L; Burgess C; Chen YH; Hart D; Platton S; Pasi J; Liesner R
Haemophilia; 2015 Jan; 21(1):e44-50. PubMed ID: 25112927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
